Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

The latest

PĪ±+ Psychedelic Bulletin #190: ā€˜Europeā€™s Most Feared Investorā€™ Teams Up with Musk Associate to Fund Lykos Therapeutics

ā€˜Europeā€™s Most Feared Investorā€™ Teams Up with Musk Associate to Fund Lykos Therapeutics ā€¢ Risk-Off or Reality Check? Psychedelic Stocks Slump After RFK Jr. Surge ā€¢ Beckley Wraps Enrolment for Phase 2b Study of 5-MeO-DMT in Treatment-Resistant Depression ā€¢ PATH Caucus RFI Submissions Roll In ā€¢ Australian VA Mulls Funding Psychedelic Therapy ā€¢ First Sponsored LSD Trial in the UK ā€¢ and more…

A Rundown of Coloradoā€™s Natural Medicine Program

Now that the rules for Coloradoā€™s regulated psychedelics program are set and license applications are open, Healing Advocacy Fundā€™s Colorado Director Tasia Poinsatte provides a brief, straightforward overview of the program and its key regulations.

PĪ±+ Psychedelic Bulletin #189: Psychedelic Philanthropists Weigh In on New Administration; Washington Lawmakers, Experts, Residents Debate Psychedelics Bills; Compass and GH Share Updates

ā€œIā€™ve Never Been More Hopefulā€ ā€” Psychedelic Philanthropists Weigh In on New Administration ā€¢ Psilocybin and Ibogaine Bills Spark Debate Among Washington State Lawmakers, Medical Experts, and Psychedelic Community ā€¢ Johns Hopkins Opens Clinic to Treat Individuals Experiencing Post-Psychedelic Difficulties ā€¢ Compass Shares Q4ā€™24 and FYā€™24 Results, PTSD Development Back on the Agenda ā€¢ GH Research Shares FYā€™24 Results, Hopes to Submit FDA Hold Response By Mid-Year ā€¢ and more…

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

TheĀ Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our PĪ±+ subscribers, with new content added regularly.

PĪ±+ Library: Bifurcated Scheduling

PĪ±+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

PĪ±+ Library: Psychedelic REMS

PĪ±+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.